The role of active vaccination in cancer immunotherapy: lessons from clinical trials

Sanda, Martin G.

doi:10.1016/j.coi.2015.05.004

Cited by 30 publications

(43 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is best exemplified by the results of the recent randomized phase III trial in NSCLC patients receiving adjuvant MAGE-A3 vaccine (47). Although the primary selection of the CTA seems of natural importance, numerous other factors, like type of adjuvant, vaccination schedule, and the patient's HLA also play major roles in the successful induction of an anticancer response (48)(49)(50)(51). These results support that more work is needed to understand the molecular mechanisms that induce anticancer immune response.…”

Section: Figure 9 Network Analysis Of Cancer Testis Antigens (Ctas) mentioning

confidence: 52%

Profiling cancer testis antigens in non–small-cell lung cancer

Djureinovic¹,

Hallström²,

Horie³

et al. 2016

JCI Insight

104

View full text Add to dashboard Cite

Section: Figure 9 Network Analysis Of Cancer Testis Antigens (Ctas) mentioning

confidence: 52%

Profiling cancer testis antigens in non–small-cell lung cancer

Djureinovic¹,

Hallström²,

Horie³

et al. 2016

JCI Insight

104

View full text Add to dashboard Cite

“…It also places CD8+ effector T cells as a central component of an effective anti-cancer response further emphasizing the role therapeutic vaccination could play in conditions of relieved immunosuppression. In clinical trials, many therapeutic vaccination schemes were shown to generate specific responses to the antigen but correlation with an objective tumor control was seldom reported [36]. Great efforts were invested to identify the relevant response and ensure the robustness and comparability of the method to evaluate it through international proficiency panels [37, 38].…”

Section: Discussionmentioning

confidence: 99%

Identification of new MUC1 epitopes using HLA-transgenic animals: implication for immunomonitoring

Scheikl-Gatard¹,

Tosch

Lemonnier

et al. 2017

J Transl Med

View full text Add to dashboard Cite

BackgroundThe success of immunotherapeutics in oncology and the search for further improvements has prompted revisiting the use of cancer vaccines. In this context, knowledge of the immunogenic epitopes and the monitoring of the immune response cancer vaccines generate are essential. MUC1 has been considered one of the most important tumor associated antigen for decades.MethodsTo identify HLA-restricted MUC1 peptides we used eight human MHC class I transgenic mouse lines, together covering more than 80% of the human population. MUC1 peptides were identified by vaccinating each line with full length MUC1 coding sequences and using an IFNγ ELIspot restimulation assay. Relevant peptides were tested in a flow cytometry-based tetramer assay and for their capacity to serve as target in an in vivo killing assay.ResultsFour previously identified MUC1 peptides were confirmed and five are described here for the first time. These nine peptide-MHC combinations were further characterized. Six gave above-background tetramer staining of splenocytes from immunized animals and three peptides were induced more than 5% specific in vivo killing.ConclusionsThese data describe for the first time five new HLA class I-restricted peptides and revisit some that were previously described. They also emphasize the importance of using in vivo/ex vivo models to screen for immunogenic peptides and define the functions for individual peptide-HLA combinations.Electronic supplementary materialThe online version of this article (doi:10.1186/s12967-017-1254-0) contains supplementary material, which is available to authorized users.

show abstract

“…La plupart des essais cliniques de phase 3 de ces vaccins ont été négatifs [25]. L'une des hypothèses émises pour expliquer ces échecs était que leur administration dans des cancers métastatiques avancés se heurtait à l'immunosuppression parallèle au stade d'avancement de la maladie.…”

Section: Vaccins Antitumorauxunclassified